Complete Randomized Design Example

Key Considerations for the FDA’s Guidance on MRD End Point in Myeloma

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

Some results have been hidden because they may be inaccessible to you